Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) (tnAcity)

2019. február 19. frissítette: Celgene

A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer

The purpose of this study is to compare the safety and efficacy of nab-paclitaxel in combination with either gemcitabine or carboplatin to the combination of gemcitabine and carboplatin as first line treatment in female subjects with triple negative metastatic breast cancer (TNMBC) or metastatic triple negative breast cancer.

A tanulmány áttekintése

Állapot

Befejezve

Körülmények

Beavatkozás / kezelés

Részletes leírás

ABI-007-MBC- 001 is a Phase 2/3, multicenter, open-label, randomized, study that will compare the safety and efficacy of weekly nab-paclitaxel in combination with gemcitabine or carboplatin to the combination of gemcitabine and carboplatin as first line therapy in female subjects with Estrogen Receptor (ER), Progesterone Receptor (PgR), and human epidermal growth factor receptor 2 (HER2) negative (triple negative) metastatic breast cancer (TNMBC) or metastatic triple negative breast cancer. In the phase 2 portion of the study, the combinations of nab-paclitaxel plus gemcitabine and nab-paclitaxel plus carboplatin will be evaluated, and a comparator arm of gemcitabine combined with carboplatin will be used. In the phase 3 portion of the study, the selected nab-paclitaxel combination treatment will be compared to gemcitabine combined with carboplatin to evaluate progression free survival, safety and tolerability, overall survival, disease control rate and duration of response in women with metastatic triple negative breast cancer.

Due to changes in the treatment landscape since the initiation of this trial, the decision was made not to proceed to the Phase 3 portion of the study.

Tanulmány típusa

Beavatkozó

Beiratkozás (Tényleges)

191

Fázis

  • 2. fázis
  • 3. fázis

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi helyek

  • Ausztria
      • Innsbruck, Ausztria, 6020
        • Universitaetsklinik Innsbruck
      • Salzburg, Ausztria, 5020
        • Salzburger Landkliniken St. Johanns-Spital
      • Vienna, Ausztria, 1090
        • Medizinische Universität Wien
  • Ausztrália
      • Nedlands, Ausztrália, 6009
        • Sir Charles Gairdner Hospital
    • Australian Capital Territory
      • Garran, Australian Capital Territory, Ausztrália, 2605
        • Canberra Hospital
    • Victoria
      • Frankston, Victoria, Ausztrália, 3199
        • Frankston Hospital Oncology Research
      • Wodonga, Victoria, Ausztrália, 3690
        • Border Medical Oncology
  • Brazília
      • Fortaleza, Brazília, 60160-230
        • ONCOCLINIC Clinica de Oncologia LTDA
      • Ribeirao Preto, Brazília, 14015-130
        • Instituto Ribeiraopretano de Combate Ao Cancer
      • Ribeirao Preto, Brazília, 14048-900
        • Hospital Das Clinicas Da Faculdade De Medicina Da USP
      • Rio Grande Do Sul, Brazília, 95900-000
        • Hospital Bruno Born
      • Sao Jose Do Rio Preto, Brazília, 15090-000
        • Hospital de Base Da Faculdade de Medicina de
      • Sao Paulo, Brazília, 05651-901
        • Hospital Albert Einstein Sociedade Beneficente Israelita Brasileira
      • São Paulo, Brazília, 01308-050
        • Sociedade Beneficente de Senhoras Hospital Sirio Libanes
      • São Paulo, Brazília, 03102-002
        • Instituto Brasileiro de Controle do Cancer Ibcc
    • Bahia
      • Salvador, Bahia, Brazília, 41820-021
        • Centro de Oncologia Da Bahia
    • Paraná
      • Curitiba, Paraná, Brazília, 81520-060
        • Liga Paranaense de Combate ao Cancer
    • Rio De Janeiro
      • Rio De Janerio, Rio De Janeiro, Brazília, 20560-120
        • Instituto Nacional de Câncer - INCA
    • Rio Grande Do Sul
      • Porto Alegre, Rio Grande Do Sul, Brazília, 90035-001
        • Associacao Hospitalar Moinhos de Vento Hospital Moinhos de Vento
      • Porto Alegre, Rio Grande Do Sul, Brazília, 90610-000
        • Hospital Sao Lucas - PUCRS
    • São Paulo
      • Barretos, São Paulo, Brazília, 14784-400
        • Fundacao Pio XII - Hospital de Cancer de Barretos
      • Jau/SP, São Paulo, Brazília, 17210-080
        • Hospital Dr. Amaral Carvalho/ Hospital Amaral Carvalho Jaú
  • Egyesült Királyság
      • Bath, Egyesült Királyság, BA1 3NG
        • Royal United Hospital
      • London, Egyesült Királyság, W1G 6AD
        • Sarah Cannon Research Institute UK
      • Manchester, Egyesült Királyság, M20 4BX
        • The Christie NHS Foundation Trust
      • Middlesex, Egyesült Királyság, HA62RN
        • The East and North Hertfordshire NHS Trust
      • Sheffield South Yorkshire, Egyesült Királyság, S10 2SJ
        • Sheffield Teaching Hospitals NHS Foundation Trust
  • Egyesült Államok
    • Arizona
      • Chandler, Arizona, Egyesült Államok, 85224
        • Ironwood Cancer and Research Center
      • Glendale, Arizona, Egyesült Államok, 85306
        • Arizona Center for Cancer Care
      • Scottsdale, Arizona, Egyesült Államok, 85259
        • Mayo Clinic Arizona
      • Scottsdale, Arizona, Egyesült Államok, 85251
        • Arizona Cancer Research Alliance
    • Arkansas
      • Fayetteville, Arkansas, Egyesült Államok, 72703
        • Highlands Oncology Group
    • California
      • Anaheim, California, Egyesült Államok, 92801
        • Pacific Cancer Medical Center Inc
      • Escondido, California, Egyesült Államok, 92025
        • California Cancer Associates for Research and Excellence cCARE
      • La Jolla, California, Egyesült Államok, 92093
        • University of California San Diego Moores Cancer Center
      • La Verne, California, Egyesült Államok, 91750
        • Wilshire Oncology Medical Group, Inc
      • Los Angeles, California, Egyesült Államok, 90045
        • Translational Research Management
      • San Luis Obispo, California, Egyesült Államok, 93401
        • Coastal Integrative Cancer Care
      • Santa Maria, California, Egyesült Államok, 93454
        • Central Coast Medical Oncology Corporation
      • Santa Rosa, California, Egyesült Államok, 95403
        • Redwood Regional Medical Group, INC
    • Florida
      • Boca Raton, Florida, Egyesült Államok, 33486
        • Center for Hematology-Oncology
      • Hollywood, Florida, Egyesült Államok, 33021
        • Memorial Breast Cancer Center
      • Jacksonville, Florida, Egyesült Államok, 32224
        • Mayo Clinic - Jacksonville
      • Miami, Florida, Egyesült Államok, 33136
        • University of Miami School of Medicine
      • Saint Petersburg, Florida, Egyesült Államok, 33705
        • Florida Cancer Specialists
      • Sarasota, Florida, Egyesült Államok, 34232
        • Florida Cancer Specialists
      • West Palm Beach, Florida, Egyesült Államok, 33401
        • Florida Cancer Specialists
    • Illinois
      • Joliet, Illinois, Egyesült Államok, 60435
        • Joliet Oncology-Hematology Associates, LTD
      • Urbana, Illinois, Egyesült Államok, 61801
        • Carle Cancer Center
    • Indiana
      • Indianapolis, Indiana, Egyesült Államok, 46254
        • Investigative Clinical Research of Indiana, LLC
    • Louisiana
      • Lafayette, Louisiana, Egyesült Államok, 70503
        • University of South Alabama Mitchell Cancer Institute
    • Maryland
      • Baltimore, Maryland, Egyesült Államok, 21201
        • University of Maryland School of Med
      • Bethesda, Maryland, Egyesült Államok, 20817
        • Center for Cancer and Blood Disorders, PC
    • Michigan
      • Detroit, Michigan, Egyesült Államok, 48202-268
        • Henry Ford Medical Center - New Center One
    • Minnesota
      • Minneapolis, Minnesota, Egyesült Államok, 55407
        • Minnesota Oncology Hematology, Pa
      • Rochester, Minnesota, Egyesült Államok, 55905
        • Mayo Clinic
    • Missouri
      • Kansas City, Missouri, Egyesült Államok, 64132
        • Midwest Physicians Group
      • Saint Louis, Missouri, Egyesült Államok, 63131
        • Missouri Baptist Medical Center
    • New Hampshire
      • Hooksett, New Hampshire, Egyesült Államok, 03106
        • New Hampshire Oncology Hematology
      • Lebanon, New Hampshire, Egyesült Államok, 03756
        • Dartmouth Hitchcock Medical Center Norris Cotton Cancer Center
    • New Jersey
      • Englewood, New Jersey, Egyesült Államok, 07631
        • Englewood Hospital and Medical Center
    • New York
      • East Syracuse, New York, Egyesült Államok, 13057
        • Hematology Oncology Associates of CNY
      • Lake Success, New York, Egyesült Államok, 11042
        • NYU Langone Arena Oncology
      • New York, New York, Egyesült Államok, 10021
        • Clinical Research Alliance
    • North Carolina
      • Burlington, North Carolina, Egyesült Államok, 27215-8700
        • Alamance Regional Medical Cancer Center
    • Ohio
      • Cincinnati, Ohio, Egyesült Államok, 45242
        • Oncology Hematology Care
      • Cincinnati, Ohio, Egyesült Államok, 45219
        • University of Cincinnatti
      • Columbus, Ohio, Egyesült Államok, 43219
        • Mark H Zangmeister Center
      • Toledo, Ohio, Egyesült Államok, 43623
        • Toledo Community Oncology Program
    • Oklahoma
      • Lawton, Oklahoma, Egyesült Államok, 73505
        • Cancer Centers of Southwest Oklahoma
    • Oregon
      • Coos Bay, Oregon, Egyesült Államok, 97420
        • North Bend Medical Center
      • Portland, Oregon, Egyesült Államok, 97213
        • Providence Portland Medical Center
      • Portland, Oregon, Egyesült Államok, 97213
        • Northwest Cancer Specialists, P.C. - Hoyt
    • Pennsylvania
      • Langhorne, Pennsylvania, Egyesült Államok, 19047
        • St Mary Medical Center
      • Pittsburgh, Pennsylvania, Egyesült Államok, 15213
        • Magee Women's Hospital
    • South Carolina
      • Columbia, South Carolina, Egyesült Államok, 29210
        • South Carolina Oncology Associates
    • Tennessee
      • Chattanooga, Tennessee, Egyesült Államok, 37404
        • Chattanooga Oncology Hematology Associates
      • Nashville, Tennessee, Egyesült Államok, 37203
        • Sarah Cannon Cancer Center
    • Texas
      • Dallas, Texas, Egyesült Államok, 75231
        • Texas Oncology, PA
      • Dallas, Texas, Egyesült Államok, 75246
        • Texas Oncology, PA- Dallas
      • Fort Worth, Texas, Egyesült Államok, 76104
        • The Center for Cancer and Blood Disorders
      • Houston, Texas, Egyesült Államok, 77030
        • UT Physicians General Medicine
      • San Antonio, Texas, Egyesült Államok, 78217
        • Cancer Care Centers of South Texas - Loop
      • Tyler, Texas, Egyesült Államok, 75702
        • Texas Oncology P.A.- Tyler
    • Virginia
      • Fredericksburg, Virginia, Egyesült Államok, 22408
        • Hematology Oncology Associates of Fredericksburg
      • Portsmouth, Virginia, Egyesült Államok, 23704
        • Delta Hematologyoncology Associates
      • Richmond, Virginia, Egyesült Államok, 23230
        • Virginia Cancer Institute
    • Washington
      • Spokane, Washington, Egyesült Államok, 99208
        • Medical Oncology Associates
    • West Virginia
      • Huntington, West Virginia, Egyesült Államok, 25701
        • Edwards Comprehensive Cancer Center
    • Wisconsin
      • Green Bay, Wisconsin, Egyesült Államok, 54301
        • Saint Vincent Hospital
      • Milwaukee, Wisconsin, Egyesült Államok, 53211
        • Columbia St Marys Cancer Center
  • Franciaország
      • Clermont-Ferrand, Franciaország, 63003
        • Centre Jean Perrin
  • Görögország
      • Athens, Görögország, 11528
        • University of Athens Medical school - Regional General Hospital
      • Athens, Görögország, 15562
        • IASO General
      • Faliro, Görögország, 18547
        • Metropolitan Hospital
      • Heraklion, Görögország, 71110
        • University General Hospital of Heraklion
      • Rio Patras, Görögország, 26500
        • University General Hospital of Patras
  • Kanada
    • Ontario
      • Ottawa, Ontario, Kanada, K1H 8L6
        • Ottawa General Hospital
    • Quebec
      • Montreal, Quebec, Kanada, H2L 4M1
        • CHUM - Notre Dame
      • Quebec City, Quebec, Kanada, G1S4L8
        • Hospital du Saint Scarement Sacrement Laboratory
      • Rimouski, Quebec, Kanada, G5L5T1
        • CSSS de Rimouski Neigette
    • Saskatchewan
      • Regina, Saskatchewan, Kanada, S4T1A5
        • Alan Blair Cancer Centre at Pasqua Hosptial
  • Németország
      • Berlin, Németország, 10713
        • Sankt Gertrauden-Krankenhaus
      • Bonn, Németország, 53111
        • Facharztpraxis fur Gynakologie und Geburtshilfe
      • Frankfurt, Németország, 60431
        • Agaplesion Markus Krankenhaus
      • Freiburg, Németország, 79110
        • Praxis für interdisziplinäre Onkologie & Hämatologie
      • Heidelberg, Németország, 69120
        • Universitaetsklinikum Heidelberg
      • Hildesheim, Németország, 31134
        • Frauenärzte am Bahnhofsplatz
      • Köln, Németország, 50679
        • Schwerpunktpraxis fur Gynakologische Onkologie
      • München, Németország, 81377
        • LMU Klinikum der Universität
      • Trier, Németország, 54290
        • Krankenanstalt Mutterhaus der Borromaerinnen
      • Ulm, Németország, 89075
        • Universitatsklinikum Ulm
  • Olaszország
      • Bologna, Emilia-Romagna, Olaszország, 40138
        • Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi
      • Ferrara, Olaszország, 44124
        • Azienda Ospedaliero-Universitaria di Ferrara Arcispedale Sant' Anna
      • Genova, Olaszország, 16132
        • IRCCS AziendaOspedaliera Universitaria San Martino
      • Grosseto, Olaszország, 58100
        • Presidio Ospedaliero della Misericordia
      • Messina, Olaszország, 98158
        • Azienda Ospedaliera Ospedali Riuniti Papardo-Piemonte
      • Monza, Olaszország, 20900
        • Azienda Ospedaliera San Gerardo
      • Napoli, Campania, Olaszország, 80131
        • Azienda Ospedaliera Universitaria Federico II
      • Napoli, Campania, Olaszország, 80131
        • Istituto Nazionale per lo studio e la cura dei tumori Fondazione Giovanni Pascale
      • Padova, Olaszország, 35128
        • Istituto Oncologico Veneto
      • Reggio Emilia, Olaszország, 42100
        • Arcispedale Santa Maria Nuova
      • Roma, Olaszország, 00189
        • Azienda Ospedaliera Sant Andrea
      • Roma, Olaszország, 144
        • Istituto Nazionale Tumori Regina Elena
      • Roma, Olaszország, 00168
        • Policlinico Universitario A Gemelli
      • Rozzano (MI), Olaszország, 20089
        • Istituto Clinico Humanitas
      • Torino, Piemonte, Olaszország, 10126
        • Azienda Ospedaliera Citta Della Salute E Della Scienza Di Torino
      • Treviglio, Olaszország, 24047
        • Azienda Ospedaliera Treviglio-Caravaggio
  • Portugália
      • Evora, Portugália, 7000-811
        • Hospital Espirito Santo
      • Lisboa, Portugália, 1500-650
        • Hospital da Luz
      • Lisboa, Portugália, 1649-035
        • Hospital de Santa Maria
      • Porto, Portugália, 4200-072
        • Instituto Portugues de Oncologia do Porto, Francisco Gentil
  • Spanyolország
      • Barcelona, Spanyolország, 08036
        • Clinic Barcelona Hospital Universitari
      • Barcelona, Spanyolország, 8035
        • Hospital Universitario Vall d Hebron
      • Cordoba, Spanyolország, 14004
        • Hospital Universitario Reina Sofia
      • Madrid, Spanyolország, 28007
        • Hospital General Gregorio Maranon
      • San Sebastian, Spanyolország, 20014
        • Onkologikoa - Kutxaren Institutu Onkologikoa
      • Santiago de Compostela, Spanyolország, 15706
        • Hospital Clinico Universitario de Santiago
      • Sevilla, Spanyolország, 41071
        • Hospital Universitario Virgen Macarena
      • Zaragoza, Spanyolország, 50009
        • Hospital Universitario Miguel Servet

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

18 év és régebbi (Felnőtt, Idősebb felnőtt)

Egészséges önkénteseket fogad

Nem

Tanulmányozható nemek

Női

Leírás

Inclusion Criteria: A subject will be eligible for inclusion in this study only if all of the following criteria are met:

  1. Female subjects, age ≥ 18 years at the time informed consent is signed
  2. Pathologically confirmed adenocarcinoma of the breast

  3. Pathologically confirmed as triple negative, source documented, defined as both of the following

    1. Estrogen Receptor (ER) and Progesterone Receptor (PgR) negative: < 1% of tumor cell nuclei are immunoreactive in the presence of evidence that the sample can express ER or PgR (positive intrinsic controls)
    2. Human Epidermal Growth Factor Receptor 2 (HER2) negative as per American Society of Clinical Oncology - College of American Pathologists (ASCO/CAP) guidelines i. Immunohistochemistry (IHC) 0 or 1 Fluorescence In Situ Hybridization (FISH) negative (or equivalent negative test). Subjects with IHC 2 must have a negative by Fluorescence In Situ Hybridization (FISH),, (or equivalent negative test).
  4. Subjects with prior breast cancer history of different phenotypes (ie, ER/PgR/HER2 positive) must have pathologic confirmation of triple negative disease in at least one of the current sites of metastasis

  5. Subjects must have received prior adjuvant or neoadjuvant anthracycline therapy; unless (a) anthracycline treatment was not indicated or was not the best treatment option for the subject in the opinion of the treating physician; and (b) anthracycline treatment remains not indicated or, in the opinion of the treating physician, is not the best treatment option for the subject's metastatic disease.

    a. Newly diagnosed subjects presenting with TNMBC are eligible for the study if anthracycline treatment is not indicated or is not the best treatment option for the subject in the opinion of the treating physician.

  6. Subjects with measurable metastatic disease, defined by Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) guidelines
  7. Life expectancy ≥ 16 weeks from randomization
  8. No prior cytotoxic chemotherapy for metastatic breast cancer. Prior immunotherapy and/or monoclonal antibody therapy are acceptable. Prior treatments must have been discontinued at least 30 days prior to start of study treatment and all related toxicities must have resolved to Grade 1 or less.

  9. Prior neoadjuvant or adjuvant chemotherapy, if given, must have been completed at least 6 months before randomization with all related toxicities resolved, and documented evidence of disease progression per RECIST 1.1 guidelines is required.

    a. If prior neoadjuvant or adjuvant chemotherapy contained taxane, gemcitabine, or platinum agents, the treatment must have completed at least 12 months before randomization

  10. Prior radiotherapy must have completed before randomization, with full recovery from acute radiation side effects. At least one measurable lesion must be completely outside the radiation portal or there must be unequivocal radiologic or clinical exam proof of progressive disease within the radiation portal, in accordance with RECIST 1.1 guidelines
  11. At least 30 days from major surgery before randomization, with full recovery
  12. Eastern Cooperative Oncology Group (ECOG) performance status 0-1

  13. Subject has the following blood counts at screening:

    • Absolute Neutrophil Count (ANC) ≥ 1500/mm^2 ;
    • Platelets ≥ 100,000/mm^2 ;
    • Hemoglobin (Hgb) ≥ 9 g/dL

  14. Subject has the following blood chemistry levels at screening:

    • Aspartate aminotransferase (AST) Serum glutamic-oxaloacetic transaminase (SGOT), Alanine Aminotransferase (ALT ) Serum Glutamic Pyruvate Transaminase (SGPT) ≤ 2.5 x upper limit of normal range (ULN); if hepatic metastases present ≤ 5.0 x ULN
    • Total serum bilirubin ≤ ULN; or total bilirubin ≤ 3.0 × ULN with direct bilirubin within normal range in subjects with documented Gilbert's Syndrome
    • Creatinine clearance > 60 mL/min (by Cockcroft-Gault)

  15. Females of child-bearing potential [defined as a sexually mature women who (1) have not undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or (2) have not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time during the preceding 24 consecutive months)] must:

    • Demonstrate a negative serum pregnancy test result at screening (performed by central lab) confirmed by local negative urine pregnancy dipstick within 72 hours prior to the first dose of IP); pregnancy test with sensitivity of at least 25 mIU/mL; and
    • Either commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis) or agree to use, and be able to comply with, two physician approved effective contraception methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) without interruption for 28 days or longer as required by local guidelines, prior to starting study drug, during the study therapy (including dose interruptions), and for 28 days after discontinuation of the study or longer as required by local guidelines
  16. Females must abstain from breastfeeding starting at randomization, during study participation and for 28 days or longer as required by local guidelines, after IP discontinuation
  17. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted
  18. Able to adhere to the study visit schedule and other protocol requirements

Exclusion Criteria:

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

  1. Male subjects
  2. Concurrent chemotherapy or any other anti tumor therapy for breast cancer. Prior immunotherapy & monoclonal antibody therapy are acceptable.
  3. Subjects who received prior cytotoxic chemotherapy after incomplete resection of locoregional recurrent disease
  4. History of, or known current evidence of brain metastasis, including leptomeningeal involvement.
  5. Subjects with bone as the only site of metastatic disease
  6. Subjects with regional lymph node as the only site of metastatic disease
  7. Serious intercurrent medical or psychiatric illness, including serious active infection
  8. History of class II-IV congestive heart failure or myocardial infarction within 6 months of randomization
  9. History of other primary malignancy in the last 5 years prior to randomization. Subjects with prior breast cancer history are eligible, however, the most recently obtained biopsy must demonstrate triple negative disease (source documented). Subjects with prior history of in situ cancer or basal or localized squamous cell skin cancer are eligible.
  10. Subjects with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple uncontrolled or unstable allergies which, in the opinion of the investigator, may lead to serious complications
  11. Peripheral neuropathy Grade ≥ 2 by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0
  12. Subjects who have received an investigational product within the previous 4 weeks prior to randomization
  13. Subject is currently enrolled, or will enroll in a different clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study
  14. Pregnant or nursing women
  15. Subjects with prior hypersensitivity to nab-paclitaxel, gemcitabine, carboplatin or any other platin, or nucleoside analogue agents
  16. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
  17. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if she were to participate in the study
  18. Any condition that confounds the ability to interpret data from the study
  19. History of seropositive human immunodeficiency virus (HIV)
  20. Subjects who are receiving immunosuppressive or myelosuppressive medications that would, in the opinion of the investigator, increase the risk of serious neutropenic complications

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Elsődleges cél: Kezelés
  • Kiosztás: Véletlenszerűsített
  • Beavatkozó modell: Párhuzamos hozzárendelés
  • Maszkolás: Nincs (Open Label)

Fegyverek és beavatkozások

Résztvevő csoport / kar
Beavatkozás / kezelés
Kísérleti: nab-Paclitaxel plus Gemcitabine
Treatment Arm A: nab-Paclitaxel 125 mg/m^2 by intravenous (IV) administration over 30 minutes, followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 of each 21-day cycle by IV administration over 30 minutes
Drog: nab-Paclitaxel
nab-Paclitaxel 125 mg/m^2 by IV administration over 30 minutes on Days 1 and 8 of each 21-day treatment cycle.
Más nevek:
  • Abraxane
Drog: Gemcitabine
Gemcitabine 1000 mg/m^2 on Days 1 and 8 of each 21-day treatment cycle.
Más nevek:
  • Gemzar
Kísérleti: nab-Paclitaxel plus Carboplatin
Treatment Arm B: nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin at an Area Under the Curve (AUC) of 2 on Days 1 and 8 of each 21-day cycle by IV administration
Drog: nab-Paclitaxel
nab-Paclitaxel 125 mg/m^2 by IV administration over 30 minutes on Days 1 and 8 of each 21-day treatment cycle.
Más nevek:
  • Abraxane
Drog: Carboplatin
Carboplatin at an AUC of 2 on Days 1 and 8 of each 21-day cycle by IV administration
Más nevek:
  • Paraplatin AQ
  • Paraplatin,
Aktív összehasonlító: Gemcitabine plus Carboplatin
Treatment Arm C: Gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin AUC 2 on Days 1 and 8 of each 21-day cycle by IV administration
Drog: Gemcitabine
Gemcitabine 1000 mg/m^2 on Days 1 and 8 of each 21-day treatment cycle.
Más nevek:
  • Gemzar
Drog: Carboplatin
Carboplatin at an AUC of 2 on Days 1 and 8 of each 21-day cycle by IV administration
Más nevek:
  • Paraplatin AQ
  • Paraplatin,

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment.
Időkeret: From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C
PFS was defined as the time from the date of randomization to the date of disease progression or death from any cause on or prior to the data cutoff date for the statistical analysis, whichever occurred earlier. Tumor responses were assessed every 6 weeks using, Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and defined as: Complete response (CR) is the disappearance of all target lesions; Partial response (PR) occurs when at least a 30% decrease in the sum of diameters of target lesions from baseline; Stable disease is neither sufficient shrinkage to qualify for a PR nor sufficient increase of lesions to qualify for Progressive disease (PD); Progressive Disease- is at least a 20% increase in the sum of diameters of target lesions from nadir.
From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Percentage of Participants With an Objective Complete or Partial Overall Response by Investigator Assessment.
Időkeret: Disease response was assessed every 6 weeks; from date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C
Percentage of participants with an Objective Complete or Partial Overall Response according to RECIST 1.1 and defined as: Complete response-disappearance of all target lesions; partial response at least a 30% decrease in the sum of diameters of target lesions from baseline; stable disease-neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for Progressive disease (PD)• Progressive Disease- At least a 20% increase in the sum of diameters of target lesions from nadir.
Disease response was assessed every 6 weeks; from date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C
Percentage of Participants Who Initiated Cycle 6 Receiving Doublet Combination Therapy
Időkeret: Cycle 6
The percentage of participants who initiated Cycle 6 receiving doublet combination therapy regardless of the need for dose modifications.
Cycle 6
Kaplan-Meier Estimates of Overall Survival
Időkeret: From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C
Overall survival was defined as the time from the date of randomization to the date of death (from any cause).
From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Időkeret: From randomization through to 28 days after the last dose of IP; up to data cut off date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C
Treatment-emergent adverse events (TEAEs) were defined as any AEs that began or worsened with the onset date on or after the date of the first dose of IP through 28 days after the last dose. A serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was graded based on the participant's symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0); AEs were evaluated for severity as follows: Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening; Grade 5 = Death.
From randomization through to 28 days after the last dose of IP; up to data cut off date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C
Percentage of Participants Experiencing Dose Modifications (Reductions and Interruptions)
Időkeret: From randomization through to 28 days after the last dose of IP; up to data-cut off of date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C
The number of participants with dose modifications occurring during the treatment period. Dose reductions and interruptions are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities.
From randomization through to 28 days after the last dose of IP; up to data-cut off of date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C
Percentage of Participants Who Discontinued From All Study Treatment Due to TEAEs
Időkeret: From randomization through to 28 days after the last dose of IP; up to data-cut off of date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C
Treatment-emergent adverse events (TEAEs) were defined as any AEs that begin or worsen with an onset date on or after the date of the first dose of IP through 28 days after the last dose.
From randomization through to 28 days after the last dose of IP; up to data-cut off of date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Szponzor

Celgene

Nyomozók

  • Tanulmányi igazgató: Ileana Elias, M.D., Celgene Corporation

Publikációk és hasznos linkek

A vizsgálattal kapcsolatos információk beviteléért felelős személy önkéntesen bocsátja rendelkezésre ezeket a kiadványokat. Ezek bármiről szólhatnak, ami a tanulmányhoz kapcsolódik.

Általános kiadványok

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete (Tényleges)

2013. szeptember 26.

Elsődleges befejezés (Tényleges)

2016. október 28.

A tanulmány befejezése (Tényleges)

2016. október 28.

Tanulmányi regisztráció dátumai

Először benyújtva

2013. június 17.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2013. június 17.

Első közzététel (Becslés)

2013. június 19.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2019. február 21.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2019. február 19.

Utolsó ellenőrzés

2019. február 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

Kulcsszavak

További vonatkozó MeSH feltételek

Egyéb vizsgálati azonosító számok

  • ABI-007-MBC-001
  • 2013-000113-20 (EudraCT szám)

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Klinikai vizsgálatok a Mellrák

Klinikai vizsgálatok a nab-Paclitaxel

Keressen hasonló próbaverziókban

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

CROs by country

CROs in Angola

Körülmények

Ritka betegségek

Kábítószer-beavatkozások

Táplálék-kiegészítők

Szponzor / közreműködők

Helyek

3
Iratkozz fel